These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
147 related items for PubMed ID: 9733145
1. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH). Monti S, Di Silverio F, Toscano V, Martini C, Lanzara S, Varasano PA, Sciarra F. J Androl; 1998; 19(4):428-33. PubMed ID: 9733145 [Abstract] [Full Text] [Related]
2. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide. Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD. J Androl; 1997; 18(5):488-94. PubMed ID: 9349746 [Abstract] [Full Text] [Related]
3. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens. Monti S, Di Silverio F, Iraci R, Martini C, Lanzara S, Falasca P, Poggi M, Stigliano A, Sciarra F, Toscano V. J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606 [Abstract] [Full Text] [Related]
4. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V. Prostate; 1998 Oct 01; 37(2):77-83. PubMed ID: 9759701 [Abstract] [Full Text] [Related]
5. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue. Sciarra F, Monti S, Adamo MV, Palma E, Toscano V, d'Eramo G, di Silverio F. Urol Res; 1995 Oct 01; 23(6):387-90. PubMed ID: 8788277 [Abstract] [Full Text] [Related]
6. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. Krieg M, Bartsch W, Thomsen M, Voigt KD. J Steroid Biochem; 1983 Jul 01; 19(1A):155-61. PubMed ID: 6193338 [Abstract] [Full Text] [Related]
8. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. van der Sluis TM, Vis AN, van Moorselaar RJ, Bui HN, Blankenstein MA, Meuleman EJ, Heijboer AC. BJU Int; 2012 Jan 01; 109(2):176-82. PubMed ID: 21992222 [Abstract] [Full Text] [Related]
9. [Measurement of T and DHT contents in normal and diseased human prostate tissues]. Zhang Y, Ye L, Ding Q, Fang Z, Yao M, Shi D. Zhonghua Wai Ke Za Zhi; 2000 Jul 01; 38(7):545-7. PubMed ID: 11832106 [Abstract] [Full Text] [Related]
10. Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia. Petrangeli E, Sciarra F, Di Silverio F, Toscano V, Lubrano C, Conti C, Concolino G. J Steroid Biochem; 1988 Jul 01; 30(1-6):395-9. PubMed ID: 2455099 [Abstract] [Full Text] [Related]
11. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, Eis V, Urban M, Mandys V. Steroids; 2007 Apr 01; 72(4):375-80. PubMed ID: 17368496 [Abstract] [Full Text] [Related]
12. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L. J Clin Endocrinol Metab; 1989 Feb 01; 68(2):461-8. PubMed ID: 2465302 [Abstract] [Full Text] [Related]
13. Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog. Moore RJ, Gazak JM, Quebbeman JF, Wilson JD. J Clin Invest; 1979 Oct 01; 64(4):1003-10. PubMed ID: 90055 [Abstract] [Full Text] [Related]
14. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens. Monti S, Di Silverio F, Lanzara S, Varasano P, Martini C, Tosti-Croce C, Sciarra F. Steroids; 1998 Oct 01; 63(5-6):362-6. PubMed ID: 9618803 [Abstract] [Full Text] [Related]
15. Clinical study on estramustine binding protein (EMBP) in human prostate. Shiina H, Igawa M, Ishibe T. Prostate; 1996 Sep 01; 29(3):169-76. PubMed ID: 8827085 [Abstract] [Full Text] [Related]
16. Supranormal nuclear content of 5 alpha-dihydrotestosterone in benign hyperplastic prostate of humans. Meikle AW, Collier ES, Middleton RG, Fang SM. J Clin Endocrinol Metab; 1980 Oct 01; 51(4):945-7. PubMed ID: 6158523 [Abstract] [Full Text] [Related]
17. Estradiol/androgen receptors during aging: microsomal distribution in human benign prostatic hypertrophy. Salazar EL, Calzada L, Escontria M. Arch Androl; 2005 Oct 01; 51(1):49-53. PubMed ID: 15764417 [Abstract] [Full Text] [Related]
18. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. Prostate Cancer Prostatic Dis; 2007 Oct 01; 10(2):149-54. PubMed ID: 17189955 [Abstract] [Full Text] [Related]
19. Conversion of 3H-testosterone to dihydrotestosterone in human hypertrophic prostatic tissue. Baranowska B, Zgliczyński S. Nuklearmedizin; 1979 Oct 01; 18(6):297-9. PubMed ID: 94161 [Abstract] [Full Text] [Related]
20. Androgen receptor isoforms in human and rat prostate. Xia SJ, Hao GY, Tang XD. Asian J Androl; 2000 Dec 01; 2(4):307-10. PubMed ID: 11202423 [Abstract] [Full Text] [Related] Page: [Next] [New Search]